Esbriet achieved a numerical difference in all-cause mortality in three phase 3 trials

All-cause mortality: No statistically significant difference over the study and follow-up period (up to 120 weeks for available patients) 1,14

ASCEND, CAPACITY 004, and CAPACITY 006 exploratory survival analysis vs placebo
Cumulative risk of all-cause mortality through study and follow-up (120 weeks)

HR=hazard ratio; CI=confidence interval.
*No statistically significant difference over the study and follow-up period (up to 120 weeks for available patients).

 

Multinational, randomized, double-blind, placebo-controlled studies vs placebo 1,2

  • Primary FVC endpoint was measured at 52 weeks for ASCEND and at 72 weeks for CAPACITY 004 and CAPACITY 006 1
  • All-cause mortality was assessed over the 120 weeks of the study duration and available follow-up, irrespective of cause of death and whether patients continued treatment after study primary endpoint 1

 

 

EXPERT PERSPECTIVES

Watch leading healthcare professionals discuss the accurate diagnosis of IPF, the clinical efficacy and safety of Esbriet, and how to manage patients with IPF

CONTACT A REPRESENTATIVE

A representative is available to answer your questions about Esbriet

ESBRIET SAFETY AND TOLERABILITY

Learn more about the safety and tolerability profile of Esbriet